Clinical trial
Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg Bromocriptine Mesylate Capsules Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions
NCT00649168 is registered in ClinicalTrials.gov with Mylan Pharmaceuticals Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg Bromocriptine Mesylate Capsules Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2007
- Completion date
- June 30, 2007
- Enrollment
- 120 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy